US FDA IND experience

VCRO has accumulated 50+ new drug commissioning projects in the US FDA IND service, among which small molecular drugs, plant drugs, 505b2, cell therapy, gene therapy, LBP, antibody drugs, vaccines, RNA drugs, etc., are gathered in VCRO's rich experience. The US FDA IND experience accounted for the largest share of treatment experience in the cancer field, about 25%, while neurological diseases and immune diseases accounted for about 15% each.